Key result
Anakinra at 100 mg/day caused a remarkable improvement in patient outcomes, resolving pericarditis quicker and with a lower chance of recurrence compared to conventional therapy.
Why the study?
Pericarditis has a high chance of recurrence even after treatment, prompting exploration of the interleukin-1 receptor antagonist anakinra as a potential new treatment.
Does anakinra improve outcomes and reduce recurrence in patients with pericarditis?
Systematic Review (n=288)
Does anakinra improve outcomes and reduce recurrence in patients with pericarditis?
Anakinra appears to be a highly effective treatment for pericarditis, particularly in recurrent or treatment-resistant cases, leading to rapid symptom resolution and decreased recurrence rates.
Answers are grounded in this paper and cite their sources.
Anakinra improves outcomes and lowers recurrences in pericarditis; extends support for IL-1 inhibition while highlighting need for larger RCTs.
Inflammation of the pericardium is referred to as pericarditis, which can cause sharp chest pain and has a high chance of recurrence even after treatment. This review will explore anakinra, which is an interleukin-1 receptor antagonist, as a potential new treatment for pericarditis. The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching PubMed and GoogleScholar from the years 2012 to 2022. After applying inclusion and exclusion criteria, thorough screening, and quality appraisal, a total of eleven studies were included in the review; eight case reports and three clinical trials. All studies showed that 100 mg/day of anakinra caused a remarkable improvement in patient outcomes. In addition, the pericarditis resolved quicker and had a lower chance of recurrence in comparison to conventional therapy.
No takes yet. Share an insight, caveat, or question.
Cheema et al. (2022) conducted a systematic review in Pericarditis (n=288). Anakinra vs. Conventional therapy or placebo was evaluated on Patient outcomes and recurrence of pericarditis. Anakinra at 100 mg/day caused a remarkable improvement in patient outcomes, resolving pericarditis quicker and with a lower chance of recurrence compared to conventional therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: